Oncotelic JV Sapu Nano Presents Data Showing Deciparticle Platform Enables Formulation of Diverse Hydrophobic Drugs

Oncotelic Therapeutics Inc. (OTCQB: OTLC) announced that its 45%-owned joint venture, Sapu Nano, presented new data at the 2025 San Antonio Breast Cancer Symposium showing its Deciparticle nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics into sub-20 nanometer nanoparticles suitable for intravenous delivery. The findings confirm Deciparticle as a versatile, current Good Manufacturing Practice-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 clinical trial supply.

The data demonstrated the platform's ability to formulate multiple classes of hydrophobic drugs, including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides. This technological advancement matters because many promising therapeutic compounds fail to reach clinical development due to formulation challenges, particularly with hydrophobic molecules that don't dissolve easily in water-based biological systems. The ability to consistently create stable nanoparticles under 20 nanometers addresses a critical bottleneck in drug development.

Oncotelic CEO Dr. Vuong Trieu stated the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates, with Sapu003 representing the first of a broader pipeline. The platform's implications extend beyond individual drug candidates to potentially accelerate development timelines across multiple therapeutic areas by providing a standardized, scalable delivery system. For the pharmaceutical industry, this represents a potential paradigm shift in how difficult-to-formulate compounds are developed, potentially bringing more treatment options to patients faster.

The manufacturing capabilities supporting this platform are significant, as ISO-5 cleanroom standards and cGMP readiness mean the technology could move quickly from laboratory validation to clinical supply production. This reduces one of the major barriers to clinical translation for nanomedicine approaches. The full details of the presentation are available in the company's press release at https://nnw.fm/b0Qps. Investors can find additional information about Oncotelic in the company's newsroom at https://nnw.fm/OTLC.

For patients facing cancers and other diseases where hydrophobic drugs show promise but face delivery challenges, this platform technology could mean access to more effective treatments. The ability to formulate diverse drug classes into nanoparticles suitable for intravenous administration opens possibilities for improved drug targeting, reduced side effects, and enhanced therapeutic efficacy. As the pharmaceutical industry continues to develop more complex molecular entities, platforms like Deciparticle that solve fundamental formulation problems become increasingly valuable for translating scientific discoveries into practical treatments.